IFW RCE/

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: VLADIMIR NIKOLAEVICH PAK, et al

Application No.: 09/885,645

Group No.: 1642

Filed: JUNE 20, 2001

For:

Examiner: SUSAN UNGAR

ME THOD FOR TREATMENT OF MALIGNANT NEOPLASMS AND A

COMPLEX PREPARATION HAVING ANTIMALIGNANT ACTIVITY

Mail Stop RCE Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

REQUEST FOR CONTINUED EXAMINATION (RCE) (37 C.F.R. 1.114)

1. Applicant hereby requests continued examination, in accordance with 37 C.F.R. Section 1.114, for the above identified application.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) AND 1.10

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. Section 1.8(a)

37 C.F.R. Section 1.10

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No. <u>EV 481669774 US</u>
(mandatory)

TRANSMISSION

facsimile transmitted to the Patent and Trademark Office to (703) 872-9306

Date: August 20, 2004

GERALDINE MARTII
Signature

(type or print name of person certifying)

• Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

08/24/2004 SSITHIB1 00000114 09885645

01 FC:2801

385.00 OP

NOTE: 37 C.F.R. § 1.114 Request for continued examination:

"(a) If prosecution in an applicat
ion is closed, an applicant may request continued examination of the application by filing a submission and the fee set forth in
§ 1.17(e) prior to the earliest of:

- (1 Payment of the issue fee, unless a petition under § 1.313 is granted;
- (2) Abandonment of the application; or
- (3) The filing of a notice of appeal to the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. 141, or the commencement of a civil action under 35 U.S.C. 145 or 146, unless the appeal or civil action is terminated.
- (b) Prosecution in an application is closed as used in this section mans that the application is under appeal, or that the last Office action is a final action (§ 1.113), a notice of allowance (§ 1.311), or an action that otherwise closes prosecution in the application.
- (c) A submission as used in this section includes, but is not limited to, an information disclosure statement, an amendment to the written description, claims, or drawings, new arguments, or new evidence in support of patentability. If reply to an Office action under 35 U.S.C. 132 is outstanding, the submission must meet the reply requirements of § 1.111.
- (d) If an applicant timely files a submission and fee set forth in § 1.17(e), the Office will withdraw the finality of any Office action and the submission will br entered and considered. If an applicant files a request for continued examination under this section after appeal, but prior to a decision on the appeal, it will be treated as a request to withdraw the appeal and to reopen prosecution f the application before the examiner. An appeal brief under § 1.192 or a reply brief under § 1.193(b), or related papers, will not be considered a submission under this section."
- NOTE: An applicant may file a submission under 37 C.F.R. 1.114 containing only an information disclosure statement (37 C.F.R. 1.97 and 1.98) in an application subject to a notice of allowance under 35 U.S.C. § 151. An appeal brief or a reply brief (or related papers) will not be considered a submission under 37 C.F.R. 1.114. See 37 C.F.R. 1.114(d). The submission, however, may consist of the arguments in a previously filed appeal brief or reply brief, or may simply consist of a statement that incorporates by reference the arguments in a previously filed appeal brief or reply brief. In addition, a previously filed amendment after final may satisfy this submission requirement. American inventor's Protection act of 1999, Question & Answer A5.
- NOTE: Even though an RCE is improper (e.g., because it was filed before the prosecution is closed), an amendment submitted with the RCE will still be entered and considered by the examiner since it was timely filed and responsive to the non-final Office action in compliance with 37 C.F.R. 1.111. American Inventor's Protection Act of 1999, Question & Answer A4.
- WARNING: 35 U.S.C. 132(b) and Section 1.114 provide for the continued examination of an application and not examination of a continuing application). Accordingly, the Office will not permit an applicant to obtain continued examination on the basis of claims that are independent and distinct from the claims previously claimed and examined. Notice of March 10, 2000, 65 Fed Reg 14865, at 14868.
- WARNING: The provisions of 37 C.F.R. 1.114 also do not apply (1) to a provisional application; (2) an application for a utility or plant patent filed under 35 U.S.C. 111(a) before June 8, 1995; (3)) an international application filed under 35 U.S.C. 363 before June 8, 1995 (4) a patent under reexamination or (5) an application for a design patent. 37 C.F.R. § 1.114(e).
- WARNING: The PTO has pointed out why § 1.97(b) does not provide that an information disclosure statement will be considered it is filed within three months after the date of a request for continued examination under § 1.114. The PTO explained that since an RCE filing is a reply under 35 U.S.C. 132, the applicant may be entitled to patent term adjustment if the Office does not act on an application containing a request for continued examination under § 1.114 within four months. See 35 U.S.C. 154(b)(1)(A)(ii). Thus, the Office cannot delay action on RCE applications for three months to determine whether an information disclosure statement will be filed. The Office, however, is adopting provisions (§ 1.103(c)) for a limited suspension of action after the filing of a request for continued examination under § 1.114, for the applicant to obtain additional time (prior to the issuance of the next Office action) to provide an information disclosure statement (or amendments, or an affidavit or declaration) after the filing of the RCE. See Notice of August 16, 2000, "Request for Continued Examination Practice and Changes to Provisional Application Practice; Final Rule", 65 Fed. Reg., pages 50091-50105, at page 50100 (comment 11); OG: September 5, 2000, pages 13-24.

WARNING:

One of the time periods excluded from patent term adjustment is the time consumed by a continued examination request under 35 U.S.C. 132(b) (§ 1.114(b)(1)).

WARNING:

The Office will not suspend action in an application when a reply by the applicant is outstanding. 35 U.S.C. 133 requires an applicant to "prosecute the application" within six months of an Office action (or a shorter period as set in the Office action) to avoid abandonment of the application. If an applicant files a request for continued examination but does not also provide any submission (in reply to the prior Office action) within the period for reply to the prior Office action, the application is abandoned by operation of law (35 U.S.C. 133).

The Office will treat a request for continued examination under \S 1.114 containing a bona fide submission that is not fully responsive to the prior Office action under the practice set forth in \S 1.135(c). In addition, under the limited suspension of action provisions of \S 1.103(c), an applicant must still file a request for continued examination practice in compliance with \S 1.114, but may obtain additional time (prior to the issuance of the next Office action) to provide an information disclosure statement, amendments, or an affidavit or declaration after the filing of the request for continued examination.

See Notice of August 16, 2000. "Request for Continued Examination Practice and Changes to Provisional Application Practice; Final Rule", 65 Fed. Reg., pages 50091-50105, at page 50102 (comment 20); OG: September 5, 29000, ages 13-24, Page 50102.

WARNING:

Section 197(b) does not provide that an information disclosure statement will be considered if it is filed within three months after the date of request for continued examination under \S 1.114.

NOTE: There is no limit to the number of times the fee for continued examination may be submitted. Notice of March 10, 2000, 65 Fed. Reg. 14865. at 14868.

NOTE: Unlike a continuation application, a continued examination request can utilize the mailing procedure of 37 C.F.R. 1.8. See 37 C.F.R. Section 1.8(a)(2)(i)(A).

TIME REQUEST IS BEING MADE

his reque	st is bein	g submitt	ted (check appropriate item(s) below):
i.	[X]	Prior to	abandonment of the application
ii.	[X]	Payment [X]	Prior to payment of issue fee Issue fee has been paid but a petition under Section 1.313 has been granted
iii.	[X]	Prior to	a decision on appeal to the Board of Patent Appeals & Interferences A notice is being separately sent to the Board of Patent Appeals & Interferences that this Request for Continued Examination is being filed.
			the Board, they may refuse to vacate a decision rendered after the filing of the RCE Office of the RCE request under Section 1.114.
iv.	[X]		to the U.S. Court of Appeals of the Federal Circuit under 35 U.S.C. Commencement of a civil action under 35 U.S.C. 146 Prior to the filing of such appeal or commencement of civil action Such appeal or commencement of civil action has been terminated
	i. ii. iii.	i. [X] ii. [X] iii. [X] iii. [X]	i. [X] Prior to ii. [X] Paymer [X] [] iii. [X] Prior to [] If such a notice is not sent to but before recognition by the iv. [X] Appeal 145 or

ENCLOSURES

	not auto ssion is/	omatically enter any prior unentered amendment(s). Here are:	with as the required
	[]	Request hereby to enter unentered amendment(s) of	
	[]	An information disclosure (37 C.F.R. Section 1.98) [] Form PTO-1449 (PTO/SB/08A and 08B)	
	[X]	An amendment	
	[]	New arguments	·
	[]	New evidence in support of patentability	
WARNI	NG:	If reply to a final or non-final Office action under 35 U.S.C. 132 is meet the reply requirements of Section 1.111. 37 C.F.R. Section 1.11	outstanding, the submission must 14(b).
	[X]	Other TWO DECLARATIONS OF VLADIMIR I	PAK
		FEE FOR REQUEST (37 C.F.R. Section 1.	17(e)).
4. Th	is applic	eation is on behalf of:	
	[X]	Small entity (and status is still as small entity)	\$ 385.00
	[]	Other than a small entity	\$ 770.00
		Continued Prosecution Request Fee	\$ <u>385.00</u>
		FEE FOR CLAIMS	
NOTE:		for continued examination under Section 1.114 (Section 1.17(e)) doe (d)(3)(ii))." See Notice of March 10, 2000, 65 Fed Reg 14865, at 14.	
	37 C.F.I	R. $1.53(d)(3)$: "The filing fee for a continued prosecution application	filed under this paragraph is:
		(i) The basic filing fee as set forth in Section 1.16; and	
		(ii) Any additional Section 1.16 fee due based on the number of cla after entry of any amendment accompanying the request for an app entry of any amendments under Section 1.116 unentered in the prio requested to be entered in the continued prosecution application."	lication under this paragraph and

5. The fee for claims (37 C.F.R. Section 1.16(b)-(d)) has been calculated as shown below:

					Total Addit. Fee	\$	OR	Total Addit. Fee	 \$
[] First	t Presentation	on of Mult	tiple Dependen	t Claim	+ \$145 =	= \$		+ \$290 =	\$
Indep.	*	Minus	***	=	x \$43 =	\$		x \$86 =	\$
Total	* .	Minus	**	=	x \$9 =	\$		x \$18 =	\$
	Claims Remainir After Amendme	ng	Highest No. Previously Paid For	Present Extra	Rate	Addit. Fee	OR	Rate	Addit. Fee
	(Col. 1)		(Col. 2)	(Col. 3)	SMALL	ENTITY	_	THER THAI MALL ENTI	

^{*} If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3,

WARNING:

See 37 C.F.R. Section 1.116.

EXTENSION OF TIME

(If an extension of time is appropriate complete (a) or (b), as applicable)

- 6. The proceedings herein are for a patent application, and the provisions of 37 C.F.R. Section 1.136(a) apply.
 - (a) [X] Applicant petitions for an extension of time, the fees for which are set out in 37 C.F.R. Section 1.17(a)(1)-(4), for the total number of months checked below:

Extension for (months)	Fee for other than small entity	Fee for small entity	
[] one month[X] two months[] three months[] four months	\$ 110.00 \$ 420.00 \$ 950.00 \$ 1,480.00	\$ 55.00 \$ 210.00 \$ 475.00 \$ 740.00	

Fee

\$ 210.00

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

^{**} If the "Highest No. Previously Paid For" IN THIS SPACE is less than 20, enter "20".

^{***} If the "Highest No. Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1 of a prior amendment or the number of claims originally filed.

•		[]	An extension for therefor of \$ months of extension no	is deducted from			
			Exten	sion fee due with this r	equest	\$	· · · · · · · · · · · · · · · · · · ·
				OR			
	(b)	[]	Applicant believes that conditional petition and the possibility that appreciation and fee for experiments.	d authorization to pay licant has inadvertentl	the necessar	y fees to	provide for
			TOTA	L FEE(S) DUE			
WARNI	NG:	The fee f	or continued examination un	der Section 1.114 may not b	be deferred. 37	C.F.R. Se	ection 1.53(f).
7. Th	e total fe	ee(s) due	is/are:				
	Contin	ued Pros	ecution Fee (Section 1.	17(e))		\$	385.00
	Fee(s)	for addit	ional claims (if any) (So	ection 1.16(b)-(d))		\$	
	Extens	ion of tir	me fee (if any) (Section	1.17(a)(1)-(4))		\$	210.00
				Total Fee(s)) Due:	\$	595.00
			PAYMEN	T OF FEE(S) DUE			
8. Ple	ease pay	the fee(s) for this continued exam	mination application as	follows:		
	[X]	Check	is attached for the sum	of		\$	595.00
	[]	Charge	Account the st	ım of		\$	
Section	1.17(a))(1)-(4) o	ny required additional for refund overpayment to	• •	e), Section 1	.16(b)-(d) and/or
	[x]	Deposi	t Account <u>12-0425</u>				

INVENTORSHIP

NOTE: Any change of inventors must be via the procedure set forth in 37 C.F.R. Section 1.48. See Notice of March 10, 2000, 65 Fed Reg 14865, at 14868.

9.	. This application as amended names as inventors:				
	[]	the same inventors as previously designated for the claims.			
	[]	fewer than the inventors previously designated and a statement accompanies this request for the deletion of the name or names of the person or persons who are not inventors of the invention now being claimed.			
	[]	a person not named previously as an invention of the separately: [] being filed [] been filed	entor and a petition under 37 C.F.R. Section		
		DEFERRAL OF EXA	MINATION		
10.	[]	A Request for Suspension of examination accompanies this request for continued examination. (See, 9-68 or Petition for Suspension)			
			•		
			Gand O Con		
			SIGNATURE OF PRACTITIONER		
Reg. No.: 33,778			JANET I. CORD (type or print name of practitioner)		
Tel	. No.: (21	2)708-1935	P.O. Address		
Customer No.: 00140			c/o Ladas & Parry LLP 26 West 61 st Street New York, N.Y. 10023		
			11011 101K, 11.1.10025		

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VLADIMIR NIKOLAEVICH PAK, et al

Application No.: 09/885,645

Group No.: 1642

Filed: JUNE 20, 2001

Examiner: SUSAN UNGAR

For:

METHOD FOR TREATMENT OF MALIGNANT NEOPLASMS AND A COMPLEX PREPARATION HAVING ANTIMALIGNANT ACTIVITY

Mail Stop RCE **Commissioner for Patents** P. O. Box 1450 Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10*

with sufficient postage as first class mail. \boxtimes

as "Express Mail Post Office to Addressee" Mailing Label No. EV 481669774 US

(mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: August 20, 2004

GERALDINE MARTI

(type or print name of person certifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail"

mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed.

Reg. 56,439, at 56,442.

08/24/2004 SSITHIB1 00000114 09885645

02 FC:2252

210.00 OP